🇺🇸 Glyceroltrinitrat in United States
143 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 143
Most-reported reactions
- Hypertension — 28 reports (19.58%)
- Dizziness — 22 reports (15.38%)
- Pain — 19 reports (13.29%)
- General Physical Health Deterioration — 15 reports (10.49%)
- Tachycardia — 14 reports (9.79%)
- Fall — 13 reports (9.09%)
- Abdominal Pain Upper — 8 reports (5.59%)
- Dyspnoea Exertional — 8 reports (5.59%)
- Hypokalaemia — 8 reports (5.59%)
- Hyponatraemia — 8 reports (5.59%)
Other Metabolic approved in United States
Frequently asked questions
Is Glyceroltrinitrat approved in United States?
Glyceroltrinitrat does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Glyceroltrinitrat in United States?
University Hospital, Basel, Switzerland is the originator. The local marketing authorisation holder may differ — check the official source linked above.